Diurnal Receives Patent Grant from European Patent Office
Diurnal Group has been granted a patent for its hydrocortisone granules in capsules for opening, Alkindi, from the European Patent Office.
Specialty pharmaceutical company, Diurnal Group, has announced the receipt of a patent for its hydrocortisone granules in capsules for opening, Alkindi, from the European Patent Office. The company revealed the news in a Nov. 20, 2020 press release.
Patent EP2780003 for the medical use of Alkindi in the treatment of pediatric patients with adrenal insufficiency, will protect Diurnal’s product in the European market until 2032. Equivalent patents have already been granted in the United Kingdom, Japan, Australia, Israel, South Africa, South Korea, and the United States (for Alkindi Sprinkle).
“With the rapid commercialization of Alkindi being a core focus for Diurnal, we are pleased to receive this patent grant by the European Patent Office,” said Martin Whitaker, CEO of Diurnal, in the press release. “This patent, which builds on our strong global intellectual property position for the product, provides protection in Europe until 2032, supporting our continued commitment to provide Alkindi to pediatric patients suffering from adrenal insufficiency.”
Source: Diurnal
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
